benzphetamine — Medica
Weight Loss
Initial criteria
- age ≥ 16 years
- patient has engaged in a trial of behavioral modification and dietary restriction for at least 3 months
- baseline BMI ≥ 30 kg/m2 OR (baseline BMI ≥ 27 kg/m2 AND at least one weight-related comorbidity: hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, cardiovascular disease, knee osteoarthritis, asthma, chronic obstructive pulmonary disease, metabolic-dysfunction associated steatotic liver disease/nonalcoholic fatty liver disease, polycystic ovarian syndrome, or coronary artery disease)
- medication will be used concomitantly with behavioral modification and a reduced-calorie diet
Reauthorization criteria
- age ≥ 16 years
- baseline BMI ≥ 30 kg/m2 OR (baseline BMI ≥ 27 kg/m2 AND at least one weight-related comorbidity: hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, cardiovascular disease, knee osteoarthritis, asthma, chronic obstructive pulmonary disease, metabolic-dysfunction associated steatotic liver disease/nonalcoholic fatty liver disease, polycystic ovarian syndrome, or coronary artery disease)
- patient has lost ≥ 5% of baseline body weight
- medication will be used concomitantly with behavioral modification and a reduced-calorie diet
Approval duration
initial: 3 months; continuation: 1 year